Quick Answer
Bluejay Diagnostics, Inc. reported Cash And Cash Equivalents At Carrying Value of $5.16 million for the year ending 2025.
- Bluejay Diagnostics, Inc. showed an increase of +20.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Bluejay Diagnostics, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $2.33 million | Q1 2022: $17.12 million | Q2 2022: $15.34 million | Q3 2022: $13.29 million | Q1 2023: $6.78 million | Q2 2023: $5.10 million | Q3 2023: $5.08 million | Q1 2024: $2.66 million | Q2 2024: $8.06 million | Q3 2024: $5.76 million | Q1 2025: $3.12 million | Q2 2025: $4.44 million | Q3 2025: $3.08 million.
- Over the full 6 years of available data (2020 to 2025), Bluejay Diagnostics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 466.1%.
- Historical annual values: Fiscal year 2025: $5.16 million | Fiscal year 2024: $4.30 million | Fiscal year 2023: $2.21 million | Fiscal year 2022: $10.11 million | Fiscal year 2021: $19.05 million | Fiscal year 2020: $912.4 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: